Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:41:33.230Z.
Calculation as of: 2026-10-06T19:41:33.230Z.
Quote observation: 2026-10-06T19:40:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 31946573a42b73cd13b381604bc2f467f5098c78190e00cee0d2639f3054c777
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
4D Molecular Therapeutics, Inc.
Market Cap
$658.16M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$666.85M
EV/FCF Ratio
13.12x
TTM Avg
10.66x
3Y Avg
30.61x
5Y Avg
30.61x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $658.16M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | 13.12x | 10.66x | 30.61x | 30.61x |
| Helus Pharma Inc. (HELP)vs › | $660.66M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $658.58M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $664.38M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $674.85M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $679.05M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $688.55M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $637.85M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $685.85M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
